Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience

被引：0

作者：

Yoshihide Ueda

Toru Ikegami

Nobuhisa Akamatsu

Akihiko Soyama

Masahiro Shinoda

Ryoichi Goto

Hideaki Okajima

Tomoharu Yoshizumi

Akinobu Taketomi

Yuko Kitagawa

Susumu Eguchi

Norihiro Kokudo

Shinji Uemoto

Yoshihiko Maehara

机构：

[1] Kyoto University,Department of Gastroenterology and Hepatology, Graduate School of Medicine

[2] Kyushu University,Department of Surgery and Science, Graduate School of Medical Sciences

[3] University of Tokyo,Division of Artificial Organ and Transplantation, Department of Surgery

[4] Nagasaki University Graduate School of Biomedical Sciences,Department of Surgery

[5] Keio University School of Medicine,Department of Surgery

[6] Hokkaido University Graduate School of Medicine,Department of Gastroenterological Surgery I

[7] Kyoto University,Department of Surgery, Graduate School of Medicine

来源：

Journal of Gastroenterology | 2017年 / 52卷

关键词：

Hepatitis C; Liver transplantation; Living donor; Sofosbuvir; Ledipasvir;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：986 / 991

页数：5

共 52 条

[1]

Berenguer M(2013)Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment J Hepatol 58 1028-1041

[2]

Schuppan D(2012)Liver transplantation in the setting of chronic HCV Best Pract Res Clin Gastroenterol 26 531-548

[3]

Terrault N(2016)Interferon-free therapy for hepatitis C in liver transplant recipients Transplantation 100 54-60

[4]

Ueda Y(2015)Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus Hepatology 62 932-954

[5]

Uemoto S(2014)Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection Hepatology 59 2083-2091

[6]

Kumada H(2016)Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation Transpl Int 29 119-121

[7]

Suzuki Y(1997)New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a J Clin Microbiol 35 201-207

[8]

Ikeda K(2015)Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 649-659

[9]

Ueda Y(2016)Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial Lancet Infect Dis 16 685-697

[10]

Uemoto S(2016)Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real-world experience from the hepatitis C therapeutic registry and research network Liver Transplant 22 24-33

← 1 2 3 4 5 6 →